Apic Bio Launches to Advance First-in-Class Gene Therapy for Treatment of Alpha-1 Antitrypsin Deficiency (Alpha 1)                       ...

[Read More...]

Fellowship will advance therapeutic strategies for Alpha-1 Antitrypsin DeficiencyCiting “substantial progress” in the first year of a postdoctoral fellowship at the National Institutes of Health’s (NIH) National Center for Advancing Translational Sci...

[Read More...]

Inhibrx’s AAT-Fc therapeutic should benefit patients with enhanced efficacy and less frequent dosing; Alpha-1 Project collaborates with industry to accelerate drug developmentLA JOLLA, CA and MIAMI, FL, September 16, 2015—Inhibrx and The ...

[Read More...]

- RNAi Therapeutic ARC-AAT Induces Dose Dependent Reductions in Mutant AAT Protein of Greater than 95 Percent in Preclinical Studies- Long Duration of Effect with AAT Remaining Reduced by More than 80% at 6 Weeks after a Single Dose- Company ...

[Read More...]

- Alnylam Remains On Track to File Investigational New Drug (IND) Application in Mid 2015 -Cambridge, Mass., and Miami, Fla., June 19, 2014 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Alpha-1 Project (...

[Read More...]